{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:06:10Z","timestamp":1781611570709,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002641","name":"Konkuk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Patients with psoriasis are vulnerable to infections due to dysregulated immunity, use of immunosuppressive drugs, and comorbid conditions. Despite ongoing concerns regarding coronavirus disease 2019 (COVID-19) vulnerability in patients with psoriasis, evidence remains limited. This nationwide, population-based, retrospective cohort study aimed to assess the risk and severity of COVID-19 and vaccine effectiveness in patients with psoriasis, including those receiving immunomodulatory therapy, using Korean National Health Insurance Service claims data from 2018 to 2021. The primary analysis included 167,746 patients with psoriasis and 866,582 controls, revealing no significant associations between psoriasis and COVID-19 (adjusted hazard ratio [aHR]: 0.99, 95% confidence interval [CI]: 0.95\u20131.04). Conversely, the secondary analysis of 3,131 patients with psoriasis and 265,475 controls revealed significantly higher rates of severe COVID-19 in patients with psoriasis (aHR: 1.33, 95% CI: 1.08\u20131.64). While some treatment subgroups \u2014 such as the cyclosporine and methotrexate subgroups \u2014 demonstrated higher incidences of COVID-19 than the reference (nonsystemic) subgroup, these differences were not statistically significant. Furthermore, vaccine interaction effects between the duration of immunity and psoriasis or each treatment were insignificant (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Patients with psoriasis exhibited a higher risk of severe COVID-19; however, their COVID-19 susceptibility and vaccine effectiveness resembled those of the control group. Additionally, the use of immunomodulatory agents did not impact COVID-19 risk or vaccine effectiveness. These findings highlight the need for dermatologists to implement pre- and postinfection strategies tailored for patients with psoriasis.<\/jats:p>","DOI":"10.1038\/s41598-025-06495-8","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:11:35Z","timestamp":1752595895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["COVID-19 susceptibility, severity, and vaccine effectiveness in patients with psoriasis: a nationwide cohort study in South Korea"],"prefix":"10.1038","volume":"15","author":[{"given":"Young Ah","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Ae","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Beom","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"6495_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee, J. Y., Kang, S., Park, J. S. & Jo, S. J. Prevalence of psoriasis in korea: A Population-Based epidemiological study using the Korean National health insurance database. Ann. Dermatol. 29, 761. https:\/\/doi.org\/10.5021\/ad.2017.29.6.761 (2017).","journal-title":"Ann. Dermatol."},{"key":"6495_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","volume":"65","author":"M Wakkee","year":"2011","unstructured":"Wakkee, M., de Vries, E., van den Haak, P. & Nijsten, T. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J. Am. Acad. Dermatol. 65, 1135\u20131144. https:\/\/doi.org\/10.1016\/j.jaad.2010.08.036 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"6495_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","volume":"138","author":"J Takeshita","year":"2018","unstructured":"Takeshita, J., Shin, D. B., Ogdie, A. & Gelfand, J. M. Risk of serious infection, opportunistic infection, and herpes Zoster among patients with psoriasis in the united Kingdom. J. Invest. Dermatology. 138, 1726\u20131735. https:\/\/doi.org\/10.1016\/j.jid.2018.01.039 (2018).","journal-title":"J. Invest. Dermatology"},{"key":"6495_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2016.04.005","volume":"75","author":"DY Hsu","year":"2016","unstructured":"Hsu, D. Y., Gordon, K. & Silverberg, J. I. Serious infections in hospitalized patients with psoriasis in the united States. J. Am. Acad. Dermatol. 75, 287\u2013296. https:\/\/doi.org\/10.1016\/j.jaad.2016.04.005 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"6495_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/bjd.21595","volume":"187","author":"N Loft","year":"2022","unstructured":"Loft, N. et al. A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark. Br. J. Dermatol. 187, 353\u2013363. https:\/\/doi.org\/10.1111\/bjd.21595 (2022).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1684\/ejd.2023.4500","volume":"33","author":"YA Cho","year":"2023","unstructured":"Cho, Y. A. et al. Serious infections and tuberculosis in psoriasis patients receiving systemic therapy in korea: a nationwide population-based cohort study. Eur. J. Dermatol. 33, 287\u2013295. https:\/\/doi.org\/10.1684\/ejd.2023.4500 (2023).","journal-title":"Eur. J. Dermatol."},{"key":"6495_CR7","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/s2665-9913(21)00247-2","volume":"3","author":"F Fagni","year":"2021","unstructured":"Fagni, F. et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 3, e724\u2013e736. https:\/\/doi.org\/10.1016\/s2665-9913(21)00247-2 (2021).","journal-title":"Lancet Rheumatol."},{"key":"6495_CR8","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1016\/s2665-9913(22)00098-4","volume":"4","author":"B Mackenna","year":"2022","unstructured":"Mackenna, B. et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the opensafely platform. Lancet Rheumatol. 4, e490\u2013e506. https:\/\/doi.org\/10.1016\/s2665-9913(22)00098-4 (2022).","journal-title":"Lancet Rheumatol."},{"key":"6495_CR9","doi-asserted-by":"publisher","unstructured":"Attauabi, M. et al. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study. J. Autoimmun. 118, 102613. https:\/\/doi.org\/10.1016\/j.jaut.2021.102613 (2021).","DOI":"10.1016\/j.jaut.2021.102613"},{"key":"6495_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl. J. Med. 384, 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389 (2021).","journal-title":"N Engl. J. Med."},{"key":"6495_CR11","doi-asserted-by":"publisher","unstructured":"Neumann-Podczaska, A. et al. Clinical characteristics and survival analysis in a small sample of older COVID-19 patients with defined 60-Day outcome. Int. J. Environ. Res. Public. Health. 17 https:\/\/doi.org\/10.3390\/ijerph17228362 (2020).","DOI":"10.3390\/ijerph17228362"},{"key":"6495_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/s0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944. https:\/\/doi.org\/10.1016\/s0140-6736(22)00152-0 (2022).","journal-title":"Lancet"},{"key":"6495_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/aje\/kwp173","volume":"170","author":"B Fireman","year":"2009","unstructured":"Fireman, B. et al. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am. J. Epidemiol. 170, 650\u2013656. https:\/\/doi.org\/10.1093\/aje\/kwp173 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"6495_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13258-022-01361-7","volume":"45","author":"B Lee","year":"2023","unstructured":"Lee, B., An, J., Lee, S. &  Won, S. Rex: R-linked excel add-in for statistical analysis of medical and bioinformatics data. Genes Genomics. 45, 295\u2013305. https:\/\/doi.org\/10.1007\/s13258-022-01361-7 (2023).","journal-title":"Genes Genomics"},{"key":"6495_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.19507","volume":"184","author":"SI Cho","year":"2021","unstructured":"Cho, S. I., Kim, Y. E. & Jo, S. J. Association of COVID-19 with skin diseases and relevant biologics: a cross\u2010sectional study using nationwide claim data in South korea**. Br. J. Dermatol. 184, 296\u2013303. https:\/\/doi.org\/10.1111\/bjd.19507 (2021).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2022.07.040","volume":"87","author":"JJ Wu","year":"2022","unstructured":"Wu, J. J., Liu, J., Thatiparthi, A., Martin, A. & Egeberg, A. The risk of COVID-19 in patients with psoriasis: A retrospective cohort study. J. Am. Acad. Dermatol. 87, 1395\u20131398. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.040 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"6495_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaci.2021.01.006","volume":"147","author":"MT Patrick","year":"2021","unstructured":"Patrick, M. T. et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J. Allergy Clin. Immunol. 147, 857\u2013869e857. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.006 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"6495_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.19755","volume":"185","author":"SK Mahil","year":"2021","unstructured":"Mahil, S. K. et al. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br. J. Dermatol. 185, 80\u201390. https:\/\/doi.org\/10.1111\/bjd.19755 (2021).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using opensafely. Nature 584, 430\u2013436. https:\/\/doi.org\/10.1038\/s41586-020-2521-4 (2020).","journal-title":"Nature"},{"key":"6495_CR20","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/s2665-9913(21)00151-x","volume":"3","author":"YH Shin","year":"2021","unstructured":"Shin, Y. H. et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South korea: a nationwide cohort study. Lancet Rheumatol. 3, e698\u2013e706. https:\/\/doi.org\/10.1016\/s2665-9913(21)00151-x (2021).","journal-title":"Lancet Rheumatol."},{"key":"6495_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","volume":"147","author":"SK Mahil","year":"2021","unstructured":"Mahil, S. K. et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis\u2014insights from a global registry\u2013based study. J. Allergy Clin. Immunol. 147, 60\u201371. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.007 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"6495_CR22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb, R. E. et al. Risk of serious infection with biologic and systemic treatment of psoriasis. JAMA Dermatology. 151, 961. https:\/\/doi.org\/10.1001\/jamadermatol.2015.0718 (2015).","journal-title":"JAMA Dermatology"},{"key":"6495_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","volume":"77","author":"AS Dobry","year":"2017","unstructured":"Dobry, A. S., Quesenberry, C. P., Ray, G. T., Geier, J. L. & Asgari, M. M. Serious infections among a large cohort of subjects with systemically treated psoriasis. J. Am. Acad. Dermatol. 77, 838\u2013844. https:\/\/doi.org\/10.1016\/j.jaad.2017.07.047 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"6495_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/bjd.20659","volume":"186","author":"L Penso","year":"2022","unstructured":"Penso, L., Dray-Spira, R., Weill, A., Zureik, M. & Sbidian, E. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br. J. Dermatol. 186, 59\u201368. https:\/\/doi.org\/10.1111\/bjd.20659 (2022).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR25","doi-asserted-by":"publisher","unstructured":"Damiani, G., Pacifico, A., Bragazzi, N. L. & Malagoli, P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol. Ther. 33 https:\/\/doi.org\/10.1111\/dth.13475 (2020).","DOI":"10.1111\/dth.13475"},{"key":"6495_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2022.2161297","volume":"34","author":"KV Kwee","year":"2023","unstructured":"Kwee, K. V. et al. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID). J. Dermatological Treat. 34, 1\u201332. https:\/\/doi.org\/10.1080\/09546634.2022.2161297 (2023).","journal-title":"J. Dermatological Treat."},{"key":"6495_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","volume":"84","author":"O Baniandres-Rodriguez","year":"2021","unstructured":"Baniandres-Rodriguez, O. et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A biobadaderm cohort analysis. J. Am. Acad. Dermatol. 84, 513\u2013517. https:\/\/doi.org\/10.1016\/j.jaad.2020.10.046 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"6495_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14712598.2021.1853698","volume":"21","author":"M Talamonti","year":"2021","unstructured":"Talamonti, M. et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study. Expert Opin. Biol. Ther. 21, 271\u2013277. https:\/\/doi.org\/10.1080\/14712598.2021.1853698 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"6495_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034. https:\/\/doi.org\/10.1016\/s0140-6736(20)30628-0 (2020).","journal-title":"Lancet"},{"key":"6495_CR30","doi-asserted-by":"publisher","first-page":"e15003","DOI":"10.1111\/dth.15003","volume":"34","author":"K Kridin","year":"2021","unstructured":"Kridin, K. et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol. Ther. 34, e15003. https:\/\/doi.org\/10.1111\/dth.15003 (2021).","journal-title":"Dermatol. Ther."},{"key":"6495_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki, R. et al. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149\u2013168e117. https:\/\/doi.org\/10.1016\/j.cell.2020.11.025 (2021).","journal-title":"Cell"},{"key":"6495_CR32","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1016\/j.vaccine.2023.05.052","volume":"41","author":"T Ergun","year":"2023","unstructured":"Ergun, T. et al. Immunogenicity, efficacy, and safety of coronavac and pfizer\/biontech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study. Vaccine 41, 4287\u20134294. https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.052 (2023).","journal-title":"Vaccine"},{"key":"6495_CR33","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","volume":"4","author":"SK Mahil","year":"2022","unstructured":"Mahil, S. K. et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 4, e42\u2013e52. https:\/\/doi.org\/10.1016\/S2665-9913(21)00333-7 (2022).","journal-title":"Lancet Rheumatol."},{"key":"6495_CR34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/bjd\/ljad023","volume":"188","author":"A Kvist-Hansen","year":"2023","unstructured":"Kvist-Hansen, A. et al. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study. Br. J. Dermatol. 188, 661\u2013669. https:\/\/doi.org\/10.1093\/bjd\/ljad023 (2023).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR35","doi-asserted-by":"publisher","first-page":"1107438","DOI":"10.3389\/fimmu.2023.1107438","volume":"14","author":"GC Lodde","year":"2023","unstructured":"Lodde, G. C. et al. COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study. Front. Immunol. 14, 1107438. https:\/\/doi.org\/10.3389\/fimmu.2023.1107438 (2023).","journal-title":"Front. Immunol."},{"key":"6495_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/bjd\/ljac109","volume":"188","author":"A Al-Janabi","year":"2023","unstructured":"Al-Janabi, A. et al. The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. Br. J. Dermatol. 188, 542\u2013551. https:\/\/doi.org\/10.1093\/bjd\/ljac109 (2023).","journal-title":"Br. J. Dermatol."},{"key":"6495_CR37","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","volume":"3","author":"SK Mahil","year":"2021","unstructured":"Mahil, S. K. et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 3, e627\u2013e637. https:\/\/doi.org\/10.1016\/S2665-9913(21)00212-5 (2021).","journal-title":"Lancet Rheumatol."},{"key":"6495_CR38","doi-asserted-by":"publisher","first-page":"101858","DOI":"10.1016\/j.trim.2023.101858","volume":"79","author":"MT Al-Haideri","year":"2023","unstructured":"Al-Haideri, M. T. et al. The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence. Transpl. Immunol. 79, 101858. https:\/\/doi.org\/10.1016\/j.trim.2023.101858 (2023).","journal-title":"Transpl. Immunol."},{"key":"6495_CR39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","volume":"10","author":"A Abhishek","year":"2022","unstructured":"Abhishek, A. et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 10, 840\u2013850. https:\/\/doi.org\/10.1016\/S2213-2600(22)00186-2 (2022).","journal-title":"Lancet Respir Med."},{"key":"6495_CR40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee, J. Y., Kang, S., Park, J. S. & Jo, S. J. Prevalence of psoriasis in korea: A Population-Based epidemiological study using the Korean National health insurance database. Ann. Dermatol. 29, 761\u2013767. https:\/\/doi.org\/10.5021\/ad.2017.29.6.761 (2017).","journal-title":"Ann. Dermatol."},{"key":"6495_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi, R. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133, 377\u2013385. https:\/\/doi.org\/10.1038\/jid.2012.339 (2013).","journal-title":"J. Invest. Dermatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06495-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06495-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:11:36Z","timestamp":1752595896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06495-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6495"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06495-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Konkuk University Medical Center IRB; approval number: 36 #KUMC 2021-12-033. Written consent was waived since this study used de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Y.B.C. has received research grants from the the Konkuk University. The remaining authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25608"}}